Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study

• Príomhchruthaitheoirí: Cheryl Cohen, DrPhD (Údar), Claire von Mollendorf, MD (Údar), Linda de Gouveia, NDMedTech (Údar), Sarona Lengana, MD (Údar), Susan Meiring, MD (Údar), Vanessa Quan, MD (Údar), Arthermon Nguweneza, MSc (Údar), David P Moore, MD (Údar), Gary Reubenson, MD (Údar), Mamokgethi Moshe, MD (Údar), Shabir A Madhi, ProfPhD (Údar), Brian Eley, ProfMD (Údar), Ute Hallbauer, MD (Údar), Heather Finlayson, MD (Údar), Sheeba Varughese, MD (Údar), Katherine L O'Brien, ProfMD (Údar), Elizabeth R Zell, MSc (Údar), Keith P Klugman, ProfPhD (Údar), Cynthia G Whitney, MD (Údar), Anne von Gottberg, PhD (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Elsevier, 2017-03-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Summary: Background: The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes that are important in low-income and middle-income countries. Vaccine effectiveness estimates are scarce in these settings. South Africa replaced PCV7 with PCV13 in 2011 using...